The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till 2030

January 14, 2021
Kevin123987

Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.

 

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link

 

Key Market Insights

  • Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems
  • Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors
  • The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains
  • Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry
  • The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics
  • Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments
  • Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems; we expect the service-based revenues to grow at a CAGR of over 8%
  • In the long term, the projected opportunity for contract biomanufacturing is anticipated to be distributed across contract service providers of different sizes, scales of manufacturing and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1        Chapter Overview

3.2.       Overview of Biopharmaceuticals

 

3.3.       Expression Systems Used for Biopharmaceutical Production

3.3.1.    Microbial Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Fungal Expression Systems

3.3.1.3. Yeast Expression Systems

3.3.2.    Mammalian versus Microbial Expression Systems

 

3.4.       Microbial Manufacturing Process

3.4.1.    Cell Banking

3.4.2.    Upstream Processing

3.4.3.    Fermentation

3.4.4.    Downstream Processing

 

3.5.       Overview of Contract Manufacturing

3.6.       Need for Outsourcing Microbial Biomanufacturing Operations

3.7.       Commonly Outsourced Microbial Biomanufacturing Operations

3.8.       Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing                                        Operations

3.9.       Key Considerations while Selecting a CMO Partner

3.10.     Concluding Remarks

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Article Categories:
HEALTH

Leave a Comment